Tc-99m- and Ga-68-labeled somatostatin analogues in the evaluation of hurthle cell thyroid cancer

Clinical Nuclear Medicine

Volumn 36, Issue 9, 2011, Pages 803-804

  Gambini, Juan Pablo ^a   Quagliata, Adriana ^a   Finozzi, Rosa ^a   Serra, Pilar ^a   Lago, Graciela ^b   Gaudiano, Javier ^b   Engler, Henry ^b   Alonso, Omar ^a,b  

^a UNIVERSITY OF URUGUAY   (Uruguay)

^b Uruguayan Center of Molecular Imaging (CUDIM)   (Uruguay)

Author keywords

gallium 68 DOTA TATE; Hurthle's cell carcinoma; Tc 99m HYNIC Octreotide

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; GALLIUM 68; IODINE 131; OCTREOTIDE; SOMATOSTATIN; TECHNETIUM 99M;

AGED; ARTICLE; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; MALE; NECK CANCER; POSITRON EMISSION TOMOGRAPHY; SCINTIGRAPHY; THYROID CANCER; THYROID PARAFOLLICULAR CELL; THYROIDECTOMY;

AGED; GALLIUM RADIOISOTOPES; HUMANS; MALE; SOMATOSTATIN; TECHNETIUM; THYROID NEOPLASMS;

EID: 80051778032     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318219b15c     Document Type: Article

References (10)

1. Plachcinska A, Mikolajczak R, Maecke H, et al. Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a pilot study. Cancer Biother Radiopharm. 2004;19:261-270. (Pubitemid 38685124)
2. 68Gallium-DOTA-peptides in NET: an overview. Eur J Radiol. In press.
3. Krenning EP, Kwekkeboom DJ, Bakker WH. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731. (Pubitemid 23284773)
4. Rodrigues M, Traub-Weidinger T, Leimer M, et al. Value of 111In-DOTAlanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2005;32:1144-1151. (Pubitemid 41355940)
5. Gabriel M, Froehlich F, Decristoforo C, et al. 99mTc-EDDA/HYNIC-TOC and (18) F-FDG in thyroid cancer patients with negative (131) I whole-body scans. Eur J Nucl Med Mol Imaging. 2004;31:330-341. (Pubitemid 38314076)
6. Middendorp M, Selkinski I, Happel C, et al. Comparison of positron emission tomography with [(18) F]FDG and [(68) Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data. Q J Nucl Med Mol Imaging. 2010;54:76-83.
7. Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTAconjugated somatostatin analogues superior to those labelledwith other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982-993. (Pubitemid 46919547)
8. Hubalewska-Dydejczyk A, Kulig J, Szybinski P, et al. Radio-guided surgery with the use of [99mTc-EDDA/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract. Eur J Nucl Med Mol Imaging. 2007;34:1545-1555. (Pubitemid 47476926)
9. Gulec SA, Baum R. Radio-guided surgery in neuroendocrine tumors. J Surg Oncol. 2007;96:309-315. (Pubitemid 47509765)
10. van Essen M, Krenning EP, Kam BL, et al. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009;5:382-393.